Doxapram and developmental delay at 12 months in children born extremely preterm.
OBJECTIVE
To examine the relation of doxapram to a developmental score achieved by a structured telephone interview in a group of extremely-preterm-born children.


METHODS
Parents of 88 children born extremely preterm were contacted by telephone and interviewed by a structured questionnaire (R-PDQ) when the corrected age of their child was 9-15 mo.


RESULTS
We found that doxapram treatment was associated with a deficit in age-adjusted R-PDQ score.


CONCLUSIONS
Doxapram may have a negative effect on neurodevelopmental outcome.
Lando
Ane
A
Department of Neonatology, The Juliane Marie Centre, Copenhagen University Hospital, Copenhagen, Denmark. alando@dadlnet.dk
Klamer
Anja
A
Jonsbo
Finn
F
Weiss
Janne
J
Greisen
Gorm
G
D016022:Case-Control Studies; D002658:Developmental Disabilities / Q000139:chemically induced*; D004315:Doxapram / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D016014:Linear Models; D008297:Male; D019141:Respiratory System Agents / Q000009:adverse effects*
D019141:Respiratory System Agents; D004315:Doxapram